Susquehanna International Group, LLP P Lx Pharma Inc. Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	SELL	$0.12 - $0.3 $60 - $152	-508 Reduced 0.95%	52,728 $6,000
Q4 2022 Feb 14, 2023	BUY	$0.15 - $0.63 $1,135 - $4,770	7,572 Added 16.58%	53,236 $8,000
Q3 2022 Nov 14, 2022	BUY	$0.52 - $3.08 $4,375 - $25,915	8,414 Added 22.59%	45,664 $30,000
Q2 2022 Aug 15, 2022	SELL	$1.9 - $4.18 $121,220 - $266,684	-63,800 Reduced 63.14%	37,250 $91,000
Q1 2022 May 16, 2022	SELL	$3.54 - $8.3 $97,934 - $229,619	-27,665 Reduced 21.49%	101,050 $408,000

Q4 2021 Feb 14, 2022	SELL	$7.69 - $19.66 $326,786 - $835,451	-42,495 Reduced 24.82%	128,715 $1.03 Million
Q3 2021 Nov 15, 2021	BUY	$12.22 - $21.28 $1.39 Million - $2.42 Million	113,618 Added 197.28%	171,210 $3.3 Million
Q2 2021 Aug 11, 2021	BUY	$9.0 - $15.94 $518,328 - $918,016	57,592 New	57,592 $795,000
Q1 2018 May 15, 2018	SELL	$3.2 - $7.43 $248,659 - $577,355	-77,706 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$6.3 - $9.1 $467,422 - $675,165	-74,194 Reduced 48.84%	77,706 $536,000
Q3 2017 Nov 14, 2017	BUY	$6.08 - $7.0 $923,552 - $1.06 Million	151,900	151,900 $987,000

61.6K

Ticker PLXP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 29,137,700
Description
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other asp...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.